Trial Profile
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities post Myocardial Infarction (SOCOGAMI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Oct 2023 Results (n=42) effects and safety of empagliflozin on insulin resistance, sensitivity and beta-cell function indexes in patients with a recent acute coronary event and newly detected dysglycaemia presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 16 Apr 2023 Status changed from recruiting to completed.
- 09 Mar 2016 New trial record